PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential (NASDAQ:PTCT)
· seekingalpha.com
PTC Therapeutics (PTCT) risk-reward: Sephience revenue growth and potential ST-920 Fabry gene therapy FDA approval could lift valuation.
PTC Therapeutics ( PTCT ) is a mid-sized biotechnology company currently trading at a market value of $5.83 billion. The stock has had a great time, being up mo...